TQ-B3203

TQ-B3203 is a novel small molecule topoisomerase I inhibitor derived from camptothecin, currently in development for the treatment of advanced solid tumors. It is formulated as a liposoluble agent and administered intravenously, with ongoing clinical trials evaluating its efficacy in cancers such as colorectal cancer, lung cancer, and prostate cancer. The drug acts by inhibiting topoisomerase I, an enzyme essential for DNA replication and transcription in tumor cells, thereby exerting antiproliferative effects. TQ-B3203 has demonstrated significant inter-individual variability in pharmacokinetics influenced by factors such as body mass index (BMI), lean body weight (LBW), and direct bilirubin levels. The drug is being developed by Chia Tai Tianqing Pharmaceutical Group under Sino Biopharm.

Other names

西诺特肯Sinoteceanum